Long-Term Monitoring of AEs and Reintegrating Patients back into Community Care
The discussion focuses on protocols for monitoring long-term complications from CAR T-cell and bispecific therapies, improving patient reintegration into community care posttreatment, and enhancing communication between academic and community oncologists.
Video content above is prompted by the following:
- What protocols and processes do you have in place to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell and bispecific therapy (risk of infections, etc)?
- How can we improve the reintegration of patients into community care after receiving treatment at an academic center?
- How can we improve communication between academic and community oncologists throughout the referral and treatment process?
Recent Videos
Related Content
